PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Decisive Innovations And Cost-Saving Measures Set The Stage For Robust Financial Growth Amidst Market Challenges
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.82 |
| 52 Week High | US$36.94 |
| 52 Week Low | US$25.20 |
| Beta | 0.63 |
| 11 Month Change | -6.34% |
| 3 Month Change | 3.59% |
| 1 Year Change | -20.28% |
| 33 Year Change | -37.44% |
| 5 Year Change | -20.21% |
| Change since IPO | 6,260.29% |
Recent News & Updates
Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade)
Aug 23Pfizer: Growing Beyond Covid
Aug 13Recent updates
Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade)
Aug 23Pfizer: Growing Beyond Covid
Aug 13Pfizer Stock: It May Be Just The Beginning Of A Solid Rally
Aug 01Pfizer's Q2 Focus: Core Products And New Ventures
Jul 25Pfizer: The Inflection Point Is Here
Jul 08Pfizer: It Could Be A Bargain
Jul 02Pfizer: Seriously Undervalued At Peak Pessimism
Jun 23Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
Jun 13Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?
Jun 09
Pfizer: Too Early For A Turnaround
Jun 06Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs
May 21Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting
May 12Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | 0.7% | 0.6% |
| 1Y | -20.3% | 18.1% | 22.9% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: PFE underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PFE has not had significant price volatility in the past 3 months.
Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market cap | US$163.88b |
| Earnings (TTM) | -US$2.59b |
| Revenue (TTM) | US$55.17b |
3.0x
P/S Ratio-63.0x
P/E RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$55.17b |
| Cost of Revenue | US$21.98b |
| Gross Profit | US$33.19b |
| Other Expenses | US$35.78b |
| Earnings | -US$2.59b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 60.16% |
| Net Profit Margin | -4.70% |
| Debt/Equity Ratio | 79.4% |
How did PFE perform over the long term?
See historical performance and comparison